Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02388074 · ClinicalTrials.gov registry record · NA
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
A NA study, sponsored by bioAffinity Technologies.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT02388074 is a NA study that has completed, run by bioAffinity Technologies. The registered enrollment target is 25 participants.
The verdict
NCT02388074, a NA study, has completed, sponsored by bioAffinity Technologies.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a single center study to assess the efficacy of CyPath® Early Detection Lung Cancer Assay to detect lung cancer cells from deep lung sputum.
Interventions
- DEVICE CyPath®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-03 |
| Est. Completion | 2015-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02388074
The ClinicalTrials.gov registry entry for NCT02388074 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is bioAffinity Technologies, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CyPath® is the first listed.
NCT02388074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02388074 about?
NCT02388074 is a clinical study titled "Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer". This is a single center study to assess the efficacy of CyPath® Early Detection Lung Cancer Assay to detect lung cancer cells from deep lung sputum.
What is the current status of trial NCT02388074?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2015-03. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02388074?
The interventions under investigation include: CyPath® (DEVICE).
Who is sponsoring clinical trial NCT02388074?
This trial is sponsored by bioAffinity Technologies, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.